Who is moving to which position
The Company will reorganize its structure to more vigorously promote the initiatives set out in the medium-term management plan “DTP2027,” namely “improving the efficiency of existing businesses,” “entering new businesses (orphan drug alliances),” and “investing in human capital,” with the aim of enhancing corporate value.
The Business Development Headquarters will be newly established, and the Portfolio Management Department, Business Development Department, and Intellectual Property Department (newly established) will be transferred to it. The Overseas Department will be abolished, and its functions will be changed from the Overseas Department to the Active Pharmaceutical Ingredients Headquarters and Pharmaceutical Headquarters by product. The Human Resources and General Affairs Headquarters will be newly established, and the Human Resources and General Affairs Department and Business Support Department (newly established) will be transferred to it.
| Item | Details |
|---|---|
| Scheduled Appointment Date | 27 August 2026 |
| Reason for change | The Company will reorganize its structure to more vigorously promote the initiatives set out in the medium-term management plan “DTP2027,” namely “improving the efficiency of existing businesses,” “entering new businesses (orphan drug alliances),” and “investing in human capital,” with the aim of enhancing corporate value. |
| Details of organizational changes | The Business Development Headquarters will be newly established, and the Portfolio Management Department, Business Development Department, and Intellectual Property Department (newly established) will be transferred to it. The Overseas Department will be abolished, and its functions will be changed from the Overseas Department to the Active Pharmaceutical Ingredients Headquarters and Pharmaceutical Headquarters by product. The Human Resources and General Affairs Headquarters will be newly established, and the Human Resources and General Affairs Department and Business Support Department (newly established) will be transferred to it. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To more vigorously promote the initiatives set out in the medium-term management plan “DTP2027”—“improving the efficiency of existing businesses,” “entering new businesses (orphan drug alliances),” and “investing in human capital”—and thereby enhance corporate value.